TrovaGene Inc (NASDAQ:TROV)’s share price traded up 6.9% during mid-day trading on Monday . The stock traded as high as $0.88 and last traded at $0.93. 4,172 shares traded hands during trading, a decline of 99% from the average session volume of 628,686 shares. The stock had previously closed at $0.87.
Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded TrovaGene from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. Maxim Group reiterated a “buy” rating on shares of TrovaGene in a research report on Monday, August 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $19.17.
The stock has a market capitalization of $14.42 million, a PE ratio of -0.14 and a beta of -0.10.
TrovaGene (NASDAQ:TROV) last issued its quarterly earnings data on Friday, August 3rd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.11). The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.10 million. TrovaGene had a negative return on equity of 188.93% and a negative net margin of 2,970.66%. Equities research analysts anticipate that TrovaGene Inc will post -1.28 earnings per share for the current fiscal year.
An institutional investor recently raised its position in TrovaGene stock. Renaissance Technologies LLC increased its position in shares of TrovaGene Inc (NASDAQ:TROV) by 58.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,802 shares of the medical research company’s stock after purchasing an additional 75,131 shares during the period. Renaissance Technologies LLC owned 1.15% of TrovaGene worth $157,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.89% of the company’s stock.
TrovaGene Company Profile (NASDAQ:TROV)
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.